Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

• Үндсэн зохиолчид: Hoai‐Thu Thai (Зохиогч), Kimiko Koiwai (Зохиогч), Yoshihisa Shitara (Зохиогч), Hirotaka Kazama (Зохиогч), Jean‐Baptiste Fau (Зохиогч), Dorothée Semiond (Зохиогч), Christine Veyrat‐Follet (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Wiley, 2023-12-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of serum M‐protein kinetics and its association with p...